126 related articles for article (PubMed ID: 26779916)
1. Pharmacokinetic interaction between pazopanib and cisplatin regimen.
Imbs DC; Diéras V; Bachelot T; Campone M; Isambert N; Joly F; Jimenez M; Lafont T; Chatelut E
Cancer Chemother Pharmacol; 2016 Feb; 77(2):385-92. PubMed ID: 26779916
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
[TBL] [Abstract][Full Text] [Related]
3. Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.
Hamberg P; Mathijssen RH; de Bruijn P; Leonowens C; van der Biessen D; Eskens FA; Sleijfer S; Verweij J; de Jonge MJ
Cancer Chemother Pharmacol; 2015 Feb; 75(2):365-71. PubMed ID: 25533184
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Infante JR; Novello S; Ma WW; Dy GK; Bendell JC; Huff A; Wang Q; Suttle AB; Allen R; Xu CF; Ottesen LH; Burris HA; Adjei AA
Invest New Drugs; 2013 Aug; 31(4):927-36. PubMed ID: 23179337
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
[TBL] [Abstract][Full Text] [Related]
8. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
Hamberg P; Boers-Sonderen MJ; van der Graaf WT; de Bruijn P; Suttle AB; Eskens FA; Verweij J; van Herpen CM; Sleijfer S
Br J Cancer; 2014 Feb; 110(4):888-93. PubMed ID: 24366297
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Heath EI; Chiorean EG; Sweeney CJ; Hodge JP; Lager JJ; Forman K; Malburg L; Arumugham T; Dar MM; Suttle AB; Gainer SD; LoRusso P
Clin Pharmacol Ther; 2010 Dec; 88(6):818-23. PubMed ID: 20980999
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors.
Ganesan C; Obulareddy SJ; Fischer JH; Antonysamy MA; Jha G; Bliss RL; Dudek AZ
Am J Clin Oncol; 2016 Jun; 39(3):280-7. PubMed ID: 24577167
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Tan AR; Dowlati A; Jones SF; Infante JR; Nishioka J; Fang L; Hodge JP; Gainer SD; Arumugham T; Suttle AB; Dar MM; Lager JJ; Burris HA
Oncologist; 2010; 15(12):1253-61. PubMed ID: 21147873
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Inada-Inoue M; Ando Y; Kawada K; Mitsuma A; Sawaki M; Yokoyama T; Sunakawa Y; Ishida H; Araki K; Yamashita K; Mizuno K; Nagashima F; Takekura A; Nagamatsu K; Sasaki Y
Cancer Chemother Pharmacol; 2014 Apr; 73(4):673-83. PubMed ID: 24464355
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz HJ; Kummar S; Harvey RD; Hamilton AL; O'Neil BH; Sarantopoulos J; LoRusso P; Rudek MA; Dowlati A; Mulkerin DL; Belani CP; Gandhi L; Lau SC; Ivy SP; Newman EM
Clin Cancer Res; 2013 Jul; 19(13):3631-9. PubMed ID: 23653147
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Heath EI; Forman K; Malburg L; Gainer S; Suttle AB; Adams L; Ball H; LoRusso P
Invest New Drugs; 2012 Aug; 30(4):1566-74. PubMed ID: 21811833
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Reardon DA; Groves MD; Wen PY; Nabors L; Mikkelsen T; Rosenfeld S; Raizer J; Barriuso J; McLendon RE; Suttle AB; Ma B; Curtis CM; Dar MM; de Bono J
Clin Cancer Res; 2013 Feb; 19(4):900-8. PubMed ID: 23363814
[TBL] [Abstract][Full Text] [Related]
18. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.
Yu H; van Erp N; Bins S; Mathijssen RH; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Clin Pharmacokinet; 2017 Mar; 56(3):293-303. PubMed ID: 27534647
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
Kerklaan BM; Lolkema MP; Devriese LA; Voest EE; Nol-Boekel A; Mergui-Roelvink M; Langenberg M; Mykulowycz K; Stoebenau J; Lane S; Legenne P; Wissel P; Smith DA; Giantonio BJ; Schellens JH; Witteveen PO
Br J Cancer; 2015 Sep; 113(5):706-15. PubMed ID: 26291057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
